M. Tarabichi

Idiosyncratic and generic single nuclei and spatial transcriptional patterns in papillary and anaplastic thyroid cancers

This study uses single nuclei RNA-seq and spatial transcriptomics to analyze transcriptional patterns in papillary and anaplastic thyroid cancers, revealing idiosyncratic and generic transcriptional variations and EMT-related features.

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

This study shows that CDK4 phosphorylation status predicts response to CDK4/6 inhibitors in thyroid carcinomas and supports combining them with BRAF/MEK inhibitors to prevent resistance.

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

This study shows that CDK4 phosphorylation predicts sensitivity of malignant pleural mesothelioma to CDK4/6 inhibitors, with 80% of tumors expressing phosphorylated CDK4.

Signatures of copy number alterations in human cancer

This paper identifies 19 copy number signatures in 9,873 cancers, explaining 93% of TCGA samples, and reveals diverse mechanisms underlying copy number alterations in human cancer.

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

This study characterizes intra-tumor heterogeneity across 2,658 human cancer genomes, identifying subclonal mutations and evolutionary patterns across 38 cancer types.

The evolutionary history of 2,658 cancers

This study uses whole-genome sequencing of cancer samples to reconstruct the evolutionary history of 39 cancer types, identifying early and late-stage mutational patterns and driver genes.

Neutral tumor evolution?

The paper explores tumor evolution through subclonal analysis and discusses the role of driver and passenger mutations in cancer progression.

Distinctive desmoplastic 3D morphology associated with BRAFV600E in papillary thyroid cancers

The paper describes a distinctive 3D morphology in BRAFV600E-mutated papillary thyroid cancers where tumor cells form a sparse mesh within a proliferative stroma, challenging traditional tumor growth models.